Real-life data of survival and reasons for discontinuation of biological disease-modifying drugs ‘in’ rheumatoid arthritis

• Published in: International journal of clinical pharmacy 2021-06, Vol.43 (3), p.737-742
• Main Authors: Gomides, Ana Paula Monteiro, de Albuquerque, Cleandro Pires, Santos, Ana Beatriz Vargas, Bértolo, Manoel Barros, Júnior, Paulo Louzada, Giorgi, Rina Dalva Neubarth, Radominski, Sebastião Cezar, Resende Guimarães, Maria Fernanda B., Bonfiglioli, Karina Rossi, de Fátima Lobato da Cunha Sauma, Maria, Pereira, Ivânio Alves, Brenol, Claiton Viegas, da Mota, Licia Maria Henrique, Pinheiro, Geraldo da Rocha Castelar
• Format: Article
• Language: English
• Subjects: Autoimmune diseases; Drugs; Infliximab; Internal Medicine; Laboratories; Medical personnel; Medical records; Medicine; Medicine & Public Health; Monoclonal antibodies; Patients; Pharmacy; Rheumatoid arthritis; Rituximab; Short Research Report; Side effects; Tumor necrosis factor-α
• ISSN: 2210-7703; 2210-7711
• DOI: 10.1007/s11096-020-01171-5

Background Rheumatoid arthritis is a chronic, autoimmune disease in which treatment has evolved with a variety of therapeutic classes. Biological disease-modifying antirheumatic drugs have improved therapy; however, the continued long-term use of these drugs with sustained safety and efficacy remains a challenge. Objective The objective of this study was to analyze time of use and reasons for discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Setting It is as part of REAL (Rheumatoid Arthritis in Real Life), a multicenter project that evaluated Brazilian patients with rheumatoid arthritis in a real-life setting. Eleven referral centers for the treatment in the public network participated in the study. Methods We conducted a cross-sectional analysis of data collected in the REAL study from August to October 2015 study. The patients were submitted to clinical evaluation and analysis of medical records. Results 1125 patients were included (89.5% women; median age: 56.6 years; and disease time: 12.8 years). A total of 406 (36.09%) participants were on a biological disease-modifying antirheumatic drugs. Infliximab was the drug with the longest time of use (12 years). Most (64.4%) drug suspension episodes were due to inefficacy. Adalimumab and certolizumab had a greater number of suspensions due to primary inefficacy, while discontinuations for abatacept were due more to secondary inefficacy. Infliximab had fewer suspensions due to primary inefficacy and golimumab had fewer episodes of secondary inefficacy. Regarding side effects, infliximab was suspended a greater number of times because of clinical and laboratory side effects. Abatacept and adalimumab had fewer suspensions due to clinical side effects, and certolizumab, rituximab and tocilizumab had fewer laboratory adverse effects. Conclusion Among the biological disease-modifying antirheumatic drugs being used for long periods, infliximab had greater time of use. Most drug suspensions (64%) were due to primary or secondary inefficacy. Number of discontinuations due to clinical and laboratory adverse effects for each drug was analyzed, and these data should be confirmed by other real-life studies. Knowledge of what is happening in real life is essential to health professionals, who need to be aware of the most common adverse effects and to health managers, who aim for greater cost-effectiveness in the choice of medications.